A Phase 2 interventional study of ARN-509 and LHRH Agonist in Prostate Cancer, sponsored by Aragon Pharmaceuticals, Inc.. Completed at 5 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-11.
Sponsored by Aragon Pharmaceuticals, Inc. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing apalutamide in Prostatic Neoplasms — 14 open to participants now, 36 under way, 12 of them phase 3. apalutamide · Prostatic Neoplasms.
Among the 70 studies testing apalutamide in Prostatic Neoplasms, this one is the 32nd largest by enrollment, is one of 3 that started in 2013, is one of 37 in phase 2, and was the 2nd registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →14 of the 70 studies testing apalutamide in Prostatic Neoplasms are open now, in 11 countries. Recruiting first, the newest first:
Astellas Pharma Global Development, Inc. · Sites in Bulgaria
Ages 50–75 · Men only · Healthy volunteers
Marco Oderda · Sites in Italy
Ages 18–80 · Men only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+ · Men only
Cambridge University Hospitals NHS Foundation Trust · Sites in United Kingdom
Ages 18+ · Men only
By country, each count listing its studies:
apalutamide: first FDA approval 2018 (ERLEADA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 39 · Phase 3 16 · Phase 4 2
First in 2010; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 81 across the 70 interventional studies. Of the 29 that completed or were terminated, 16 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 70 have an industry lead sponsor. The 10 most frequent:
This study is registered under Aragon Pharmaceuticals, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Aragon Pharmaceuticals, Inc. is the lead sponsor of 16 studies on the registry; none are open to participants now.
88 studies in Prostatic Neoplasms by Johnson & Johnson: 9 open now, 23 under way, 9 of them phase 3. Of 58 finished, 24 (41%) have results posted.
Among the 88 studies in Prostatic Neoplasms by Johnson & Johnson, this one is the 33rd largest by enrollment of the 68 interventional ones that give a count, is one of 8 that started in 2013, is one of 20 in phase 2, and was the 33rd registered.
Johnson & Johnson’s Prostatic Neoplasms studies by the year they started, since 1995.
9 of the studies testing apalutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT03767244Phase 3Janssen Research & Development, LLCA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 2026-12-01 |
| NCT02531516Phase 3Aragon Pharmaceuticals, Inc.An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | 2027-03-01 |
| NCT06274047Phase 3M.D. Anderson Cancer CenterPROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer. | 2027-06-30 |
| NCT06067269Jonsson Comprehensive Cancer CenterHormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial | 2026-12-30 |
Add all 9 to your calendar (.ics) → With an account.
Among the 70 studies testing apalutamide in Prostatic Neoplasms, from their registry updates:
Among Johnson & Johnson’s 88 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The proposed clinical trial will study the effects of 12 months of therapy with ARN-509 alone, or in combination with an LHRH agonist (LHRHa), each compared with LHRHa alone, in men with a rapidly rising serum PSA after prior definitive local therapy for prostate cancer. The endpoints selected reflect measurable short term effects of androgen deprivation therapy (ADT), including quality of life and several metabolic parameters. In addition, the relative effect of each treatment strategy on PSA suppression as well as testosterone recovery (and subsequent PSA progression) after 12 months of therapy will be evaluated.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ARN-509 Tablets, 240 mg/day administered orally
Drug: ARN-509
Choice of LHRHa per investigator discretion/site practice guidelines (e.g, Eligard®, Zoladex®, Lupron Depot®, Trelstar®) and ARN-509 Tablets, 240 mg/day administered orally
Drug: ARN-509 · Drug: LHRH Agonist
Choice of LHRHa per investigator discretion/site practice guidelines (e.g., Eligard®, Zoladex®, Lupron Depot®, Trelstar®).
Drug: LHRH Agonist
Also known as: Eligard®, Lupron Depot®, Zoladex®, Trelstar®
Change From Baseline in Functional Assessment of Cancer Therapy - Prostate (FACT-P) Total Score at 12 Months
FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT- General + the Prostate Cancer Subscale (PCS). The FACT-General (FACT-G) is a 27 item Quality of Life (QoL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional Well-being (0-24). The total score range is between 1-108, higher scores indicates better for total score and subscale scores. PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better). The FACT-P total score is the sum of all 5 subscale scores of the FACT-P questionnaire and ranges from 0-156. Higher scores indicate higher degree of functioning and better quality of life.
Time frame: Baseline, at 12 months
Change From Baseline in FACT-P Total Score at 3 and 24 Months
FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT- General + the Prostate Cancer Subscale (PCS). The FACT-General (FACT-G) is a 27 item Quality of Life (QoL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional Well-being (0-24). The total score range is between 1-108, higher scores indicates better for total score and subscale scores. PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better). The FACT-P total score is the sum of all 5 subscale scores of the FACT-P questionnaire and ranges from 0-156. Higher scores indicate higher degree of functioning and better quality of life.
Time frame: Baseline, at 3 and 24 months
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score at 3, 12 and 24 Months
EORTC QLQ-C30 is a 30 items self-reporting questionnaire resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 Global Health Status (GHS) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Questionnaire includes 28 items with 4-point Likert type responses from "1-not at all" to "4-very much" to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall health related quality of life. Scores are transformed to 0 to 100 scale, with higher scores representing better GHS, better functioning, and more symptoms.
Time frame: Baseline, at 3, 12 and 24 months
Change From Baseline in EORTC Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Score at 3, 12 and 24 Months
EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It Consist of 25 questions distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions on a 4 point scale (1 'Not at all' to 4 'Very much'). All raw domain scores are linearly transformed to a 0-100 scale, with higher scores reflecting either more symptoms (urinary, bowel, hormonal treatment-related symptoms) or higher levels of activity or functioning (sexual).
Time frame: Baseline, at 3, 12 and 24 months
Change From Baseline in Sexual Health Inventory for Men (SHIM) Total Score at 3, 12, 24 Months
The SHIM is a well validated abridged 5-item of the 15-item International Index of Erectile Function, which has been extensively studied in men with erectile dysfunction due to various etiologies, including prostate cancer-related therapies. It consists of 5 items pertaining to sexual functioning, with scores ranging from 0-5 for most items. The total score is obtained by adding all five item scores, and can range from 5 to 25. Higher scores indicate higher level of sexual function and less erectile dysfunction.
Time frame: Baseline, at 3, 12, 24 months
Time to Prostate Specific Antigen (PSA) Progression Based on Modified Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria
PSA progression was defined as a rise to greater than 50 percent (%) of the baseline serum PSA or rise of 2 nanogram per milliliter (ng/mL) or more above the nadir, whichever is higher, confirmed by repeat measurement at least 2 weeks later.
Time frame: Up to 24 months
Percentage of Participants Without PSA or Radiographic Progression and With Recovery of Serum Testosterone
Percentage of participants without evidence of PSA or radiographic progression during the 24-month treatment period and with recovery of serum testosterone at 24 months were reported. Testosterone recovery was defined as a serum testosterone greater than (\>) 150 nanogram per deciliter (ng/dL). PSA progression was defined as a rise to greater than 50 percent (%) of the baseline serum PSA or rise of 2 nanogram per milliliter (ng/mL) or more above the nadir, whichever is higher, confirmed by repeat measurement at least 2 weeks later. Radiographic progression was defined as the detection of new metastasis on either bone scan or cross-sectional imaging (computed tomography \[CT\] or magnetic resonance imaging \[MRI\]).
Time frame: Up to 24 months
Percentage of Participants With a Serum PSA Less Than 0.2 ng/mL
Percentage of participants with PSA less than (\<) 0.2 ng/mL after 7 months of protocol therapy were reported.
Time frame: From 7 to 24 months
Change From Baseline in Body Mass Index (BMI)
Change from baseline in BMI was reported. BMI was calculated as 'body weight in kg/(height in meters)\* (height in meters)'. Endpoint values are from the last measurement within the analysis period.
Time frame: Baseline, Day 1 (Cycle 1), Day 28 (Cycle 1, 2, 4, 5, 7, 8, 10 and 11), Day 35 (Cycle 3, 6, 9 and 12) and endpoint (up to 24 months)
Change From Baseline in Fasting Plasma Glucose
The change from baseline in fasting plasma glucose levels was analyzed and reported using a mixed-model for repeated measures.
Time frame: Baseline, Day 35 (Cycle 3, 6, 9 and 12)
Change From Baseline in Glycated Hemoglobin (HbA1C)
The change from baseline in HbA1C was analyzed and reported using a mixed-model for repeated measures.
Time frame: Baseline, Day 35 (Cycle 3, 6, 9 and 12)
Change From Baseline in Cholesterol, High-density Lipoprotein (HDL) Cholesterol, Low-density Lipoprotein (LDL) Cholesterol and Triglycerides
Change from baseline in cholesterol, HDL cholesterol, LDL cholesterol and triglycerides were analyzed and reported using a mixed-model for repeated measures.
Time frame: Baseline, Day 35 (Cycle 3, 6, 9 and 12)
Change From Baseline in Bone Mineral Density (BMD)
Change from baseline in BMD was assessed for femoral neck and lumber spine with DEXA scans.
Time frame: Baseline, Cycle 12 Day 35
Median Time to Serum Testosterone Recovery to Greater Than (>) 50 ng/dL (Non-castrate) and > 150 ng/dL
The time to serum testosterone recovery to \> 50 ng/dL and \> 150 ng/dL from Month 13 to Month 24 of protocol therapy was reported.
Time frame: Month 13 to Month 24
Change From Baseline in Serum Dihydrotestosterone (DHT) Levels
Change from baseline in serum DHT levels was reported.
Time frame: Baseline, Day 35 (Cycle 6 and Cycle 12)
Change From Baseline in Estradiol Levels
Change from baseline in estradiol levels was reported.
Time frame: Baseline, Day 35 (Cycle 6 and Cycle 12)
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. Treatment-emergent adverse events are those that occurred between the date of 1st dose of study drug and date of last dose of study drug plus 30 days.
Time frame: From date of 1st dose of study drug to date of last dose of study drug plus 30 days (up to 6 years)
| Milestone | Luteinizing Hormone Releasing Hormone Agonist (LHRHa) | Apalutamide | LHRHa + Apalutamide |
|---|---|---|---|
| Started | 30 | 29 | 31 |
| Treated | 29 | 29 | 31 |
| Completed | 0 | 0 | 0 |
| Not completed | 30 | 29 | 31 |
| Withdrew: Psa progression | 12 | 16 | 16 |
| Withdrew: Other | 5 | 4 | 8 |
| Withdrew: Initiation of non-protocol therapy | 3 | 4 | 2 |
| Withdrew: Withdrawal by physician | 1 | 1 | 2 |
| Withdrew: Withdrawal by subject | 3 | 1 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 |
| Withdrew: Adverse event | 0 | 2 | 0 |
| Withdrew: Death | 2 | 0 | 0 |
| Withdrew: Radiographic progression | 3 | 1 | 0 |
FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT- General + the Prostate Cancer Subscale (PCS). The FACT-General (FACT-G) is a 27 item Quality of Life (QoL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional Well-being (0-24). The total score range is between 1-108, higher scores indicates better for total score and subscale scores. PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better). The FACT-P total score is the sum of all 5 subscale scores of the FACT-P questionnaire and ranges from 0-156. Higher scores indicate higher degree of functioning and better quality of life.
| Units on a scale | Luteinizing Hormone Releasing Hormone Agonist (LHRHa) | Apalutamide | LHRHa + Apalutamide |
|---|---|---|---|
| Change From Baseline in Functional Assessment of Cancer Therapy - Prostate (FACT-P) Total Score at 12 Months | -8.04 ± 2.40 | -6.60 ± 2.53 | -9.42 ± 2.30 |
FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT- General + the Prostate Cancer Subscale (PCS). The FACT-General (FACT-G) is a 27 item Quality of Life (QoL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional Well-being (0-24). The total score range is between 1-108, higher scores indicates better for total score and subscale scores. PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better). The FACT-P total score is the sum of all 5 subscale scores of the FACT-P questionnaire and ranges from 0-156. Higher scores indicate higher degree of functioning and better quality of life.
| Units on a scale | Luteinizing Hormone Releasing Hormone Agonist (LHRHa) | Apalutamide | LHRHa + Apalutamide |
|---|---|---|---|
| Change at 3 months | -2.62 ± 2.49 | -4.80 ± 2.45 | -6.72 ± 2.29 |
| Change at 24 months | -4.43 ± 2.91 | 1.84 ± 3.17 | -1.87 ± 2.59 |
EORTC QLQ-C30 is a 30 items self-reporting questionnaire resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 Global Health Status (GHS) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Questionnaire includes 28 items with 4-point Likert type responses from "1-not at all" to "4-very much" to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall health related quality of life. Scores are transformed to 0 to 100 scale, with higher scores representing better GHS, better functioning, and more symptoms.
| Units on a scale | Luteinizing Hormone Releasing Hormone Agonist (LHRHa) | Apalutamide | LHRHa + Apalutamide |
|---|---|---|---|
| Appetite loss: Change at 3 months | 2.80 ± 2.84 | 3.43 ± 2.75 | 8.04 ± 2.48 |
| Appetite loss: Change at 12 months | 3.49 ± 3.34 | 4.87 ± 3.51 | 5.70 ± 3.09 |
| Appetite loss: Change at 24 months | -2.29 ± 4.05 | -2.50 ± 4.35 | 5.28 ± 3.29 |
| Cognitive functioning: Change at 3 months | -2.44 ± 3.69 | -6.83 ± 3.62 | -7.73 ± 3.28 |
| Cognitive functioning: Change at 12 months | -2.21 ± 3.40 | -11.50 ± 3.58 | -8.27 ± 3.19 |
| Cognitive functioning: Change at 24 months | -5.08 ± 4.16 | -12.71 ± 4.64 | -4.42 ± 3.55 |
| Constipation: Change at 3 months | 2.90 ± 3.01 | -3.21 ± 2.94 | 3.45 ± 2.65 |
| Constipation: Change at 12 months | 10.12 ± 3.18 | 0.27 ± 3.36 | 7.69 ± 2.96 |
| Constipation: Change at 24 months | 0.45 ± 4.10 | 0.91 ± 4.43 | -0.10 ± 3.33 |
| Diarrhoea: Change at 3 months | 5.99 ± 4.26 | 8.10 ± 4.20 | 8.09 ± 3.77 |
| Diarrhoea: Change at 12 months | 0.02 ± 3.66 | 0.96 ± 3.87 | 3.28 ± 3.42 |
| Diarrhoea: Change at 24 months | -0.35 ± 4.49 | -1.96 ± 4.97 | 4.38 ± 3.73 |
| Dyspnoea: Change at 3 months | 6.42 ± 4.36 | 13.22 ± 4.29 | 12.85 ± 3.86 |
| Dyspnoea: Change at 12 months | 4.45 ± 4.07 | 10.32 ± 4.34 | 9.49 ± 3.82 |
| Dyspnoea: Change at 24 months | 11.16 ± 5.41 | 8.89 ± 5.86 | 7.34 ± 4.42 |
| Emotional functioning: Change at 3 months | -0.81 ± 2.79 | -2.59 ± 2.73 | 1.41 ± 2.46 |
| Emotional functioning: Change at 12 months | 1.39 ± 2.46 | 1.71 ± 2.60 | 3.84 ± 2.29 |
| Emotional functioning: Change at 24 months | -0.60 ± 3.37 | 3.59 ± 3.67 | 3.13 ± 2.77 |
| Fatigue: Change at 3 months | 11.40 ± 4.32 | 21.85 ± 4.30 | 22.40 ± 3.80 |
| Fatigue: Change at 12 months | 15.29 ± 3.97 | 13.29 ± 4.22 | 19.80 ± 3.70 |
| Fatigue: Change at 24 months | 11.33 ± 4.96 | 5.53 ± 5.49 | 5.81 ± 4.10 |
| Financial difficulties: Change at 3 months | -5.91 ± 3.39 | -1.79 ± 3.33 | 2.49 ± 3.03 |
| Financial difficulties: Change at 12 months | -6.26 ± 3.49 | 3.98 ± 3.70 | 3.90 ± 3.28 |
| Financial difficulties: Change at 24 months | -10.69 ± 4.47 | -1.56 ± 4.88 | -3.90 ± 3.71 |
| Global health status: Change at 3 months | -3.57 ± 3.45 | -10.30 ± 3.36 | -9.19 ± 3.01 |
| Global health status: Change at 12 months | -4.90 ± 3.08 | -8.28 ± 3.23 | -6.08 ± 2.85 |
| Global health status: Change at 24 months | -8.14 ± 4.14 | -3.73 ± 4.52 | -7.05 ± 3.39 |
| Insomnia: Change at 3 months | 6.88 ± 6.18 | 5.31 ± 6.08 | 14.34 ± 5.46 |
| Insomnia: Change at 12 months | 15.89 ± 5.46 | 2.71 ± 5.80 | 8.60 ± 5.12 |
| Insomnia: Change at 24 months | 16.34 ± 6.96 | 2.49 ± 7.83 | -3.00 ± 5.76 |
| Nausea and vomiting: Change at 3 months | 2.88 ± 1.56 | 3.62 ± 1.53 | 3.99 ± 1.38 |
| Nausea and vomiting: Change at 12 months | 2.08 ± 1.34 | 2.05 ± 1.43 | 3.51 ± 1.26 |
| Nausea and vomiting: Change at 24 months | 1.19 ± 1.19 | 0 ± 0 | 1.59 ± 1.09 |
| Pain: Change at 3 months | 2.57 ± 4.03 | 1.63 ± 3.95 | 3.53 ± 3.56 |
| Pain: Change at 12 months | 6.24 ± 3.89 | 4.41 ± 4.11 | 14.42 ± 3.64 |
| Pain: Change at 24 months | 2.84 ± 4.84 | 2.12 ± 5.21 | 2.99 ± 3.92 |
| Physical functioning: Change at 3 months | -1.68 ± 2.51 | -7.72 ± 2.46 | -3.87 ± 2.22 |
| Physical functioning: Change at 12 months | -4.90 ± 2.45 | -6.32 ± 2.59 | -6.78 ± 2.30 |
| Physical functioning: Change at 24 months | -7.08 ± 2.96 | -3.61 ± 3.21 | -3.80 ± 2.50 |
| Role functioning: Change at 3 months | -6.92 ± 3.94 | -4.70 ± 3.87 | -8.14 ± 3.48 |
| Role functioning: Change at 12 months | -6.55 ± 4.00 | -9.65 ± 4.24 | -12.12 ± 3.75 |
| Role functioning: Change at 24 months | -3.48 ± 4.99 | 0.08 ± 5.43 | -7.57 ± 4.06 |
| Social functioning: Change at 3 months | -5.72 ± 4.03 | -1.95 ± 3.96 | -9.57 ± 3.56 |
| Social functioning: Change at 12 months | -6.95 ± 3.69 | -0.37 ± 3.91 | -5.01 ± 3.45 |
| Social functioning: Change at 24 months | 5.15 ± 4.64 | 3.90 ± 5.06 | -2.93 ± 3.81 |
EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It Consist of 25 questions distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions on a 4 point scale (1 'Not at all' to 4 'Very much'). All raw domain scores are linearly transformed to a 0-100 scale, with higher scores reflecting either more symptoms (urinary, bowel, hormonal treatment-related symptoms) or higher levels of activity or functioning (sexual).
| Units on a scale | Luteinizing Hormone Releasing Hormone Agonist (LHRHa) | Apalutamide | LHRHa + Apalutamide |
|---|---|---|---|
| Incontinence aid: Change at 3 months | 21.74 ± 11.72 | 3.35 ± 14.22 | 12.09 ± 10.97 |
| Incontinence aid: Change at 12 months | 14.31 ± 9.92 | 15.11 ± 10.07 | 2.78 ± 9.44 |
| Incontinence aid: Change at 24 months | 20.60 ± 16.04 | 32.59 ± 12.52 | 19.46 ± 9.82 |
| Bowel symptoms: Change at 3 months | 1.43 ± 1.53 | 4.27 ± 1.49 | 5.37 ± 1.33 |
| Bowel symptoms: Change at 12 months | 5.11 ± 1.57 | 1.36 ± 1.69 | 3.76 ± 1.45 |
| Bowel symptoms: Change at 24 months | -0.82 ± 1.98 | 0.93 ± 2.09 | 1.48 ± 1.56 |
| HTRS: Change at 3 months | 10.56 ± 2.25 | 8.09 ± 2.21 | 13.32 ± 2.01 |
| HTRS: Change at 12 months | 14.72 ± 2.44 | 18.05 ± 2.59 | 19.43 ± 2.30 |
| HTRS: Change at 24 months | 6.42 ± 3.16 | 1.30 ± 3.45 | 5.39 ± 2.62 |
| Sexual activity: Change at 3 months | 20.18 ± 4.40 | 16.10 ± 4.32 | 19.78 ± 3.98 |
| Sexual activity: Change at 12 months | 33.50 ± 4.03 | 19.16 ± 4.24 | 25.02 ± 3.83 |
| Sexual activity: Change at 24 months | 13.17 ± 5.23 | 11.46 ± 5.72 | 12.56 ± 4.39 |
| Sexual functioning: Change at 3 months | 9.65 ± 9.80 | 22.03 ± 9.03 | 37.20 ± 10.73 |
| Sexual functioning: Change at 12 months | 10.65 ± 10.09 | -1.19 ± 9.05 | 10.73 ± 11.14 |
| Sexual functioning: Change at 24 months | -6.41 ± 12.58 | 12.33 ± 11.54 | 0.32 ± 11.34 |
| Urinary symptoms: Change at 3 months | 8.87 ± 2.61 | 2.55 ± 2.54 | 7.16 ± 2.28 |
| Urinary symptoms: Change at 12 months | 5.47 ± 2.45 | 1.81 ± 2.57 | 10.54 ± 2.26 |
| Urinary symptoms: Change at 24 months | 5.87 ± 3.26 | 0.52 ± 3.50 | 9.16 ± 2.70 |
The SHIM is a well validated abridged 5-item of the 15-item International Index of Erectile Function, which has been extensively studied in men with erectile dysfunction due to various etiologies, including prostate cancer-related therapies. It consists of 5 items pertaining to sexual functioning, with scores ranging from 0-5 for most items. The total score is obtained by adding all five item scores, and can range from 5 to 25. Higher scores indicate higher level of sexual function and less erectile dysfunction.
| Units on a scale | Luteinizing Hormone Releasing Hormone Agonist (LHRHa) | Apalutamide | LHRHa + Apalutamide |
|---|---|---|---|
| Change at 3 months | -3.64 ± 0.74 | -1.80 ± 0.67 | -3.54 ± 0.63 |
| Change at 12 months | -3.52 ± 0.81 | -2.91 ± 0.83 | -3.79 ± 0.78 |
| Change at 24 months | -1.97 ± 1.16 | -2.03 ± 1.17 | -2.39 ± 0.99 |
PSA progression was defined as a rise to greater than 50 percent (%) of the baseline serum PSA or rise of 2 nanogram per milliliter (ng/mL) or more above the nadir, whichever is higher, confirmed by repeat measurement at least 2 weeks later.
| Months | Luteinizing Hormone Releasing Hormone Agonist (LHRHa) | Apalutamide | LHRHa + Apalutamide |
|---|---|---|---|
| Time to Prostate Specific Antigen (PSA) Progression Based on Modified Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria | 30.88 (22.54 to NA) | 25.79 (20.04 to 38.90) | 36.11 (26.97 to 56.64) |
Percentage of participants without evidence of PSA or radiographic progression during the 24-month treatment period and with recovery of serum testosterone at 24 months were reported. Testosterone recovery was defined as a serum testosterone greater than (\>) 150 nanogram per deciliter (ng/dL). PSA progression was defined as a rise to greater than 50 percent (%) of the baseline serum PSA or rise of 2 nanogram per milliliter (ng/mL) or more above the nadir, whichever is higher, confirmed by repeat measurement at least 2 weeks later. Radiographic progression was defined as the detection of new metastasis on either bone scan or cross-sectional imaging (computed tomography \[CT\] or magnetic resonance imaging \[MRI\]).
| Percentage of participants | Luteinizing Hormone Releasing Hormone Agonist (LHRHa) | Apalutamide | LHRHa + Apalutamide |
|---|---|---|---|
| Percentage of Participants Without PSA or Radiographic Progression and With Recovery of Serum Testosterone | 19.2 | 37.0 | 37.9 |
Percentage of participants with PSA less than (\<) 0.2 ng/mL after 7 months of protocol therapy were reported.
| Percentage of participants | Luteinizing Hormone Releasing Hormone Agonist (LHRHa) | Apalutamide | LHRHa + Apalutamide |
|---|---|---|---|
| Percentage of Participants With a Serum PSA Less Than 0.2 ng/mL | 88.5 | 88.9 | 96.6 |
Change from baseline in BMI was reported. BMI was calculated as 'body weight in kg/(height in meters)\* (height in meters)'. Endpoint values are from the last measurement within the analysis period.
| Kilogram per meter square (kg/m^2) | Luteinizing Hormone Releasing Hormone Agonist (LHRHa) | Apalutamide | LHRHa + Apalutamide |
|---|---|---|---|
| Change at Cycle 1 Day 1 | 0.00 | — | 0.00 |
| Change at Cycle 1 Day 28 | 0.00 ± 0.443 | -0.02 ± 0.569 | -0.29 ± 0.458 |
| Change at Cycle 2 Day 28 | -0.06 ± 0.903 | -0.23 ± 0.616 | -0.32 ± 0.524 |
| Change at Cycle 3 Day 35 | 0.02 ± 0.837 | -0.34 ± 0.729 | -0.24 ± 0.610 |
| Change at Cycle 4 Day 28 | 0.19 ± 0.784 | -0.17 ± 0.710 | -0.12 ± 0.645 |
| Change at Cycle 5 Day 28 | 0.26 ± 0.892 | -0.15 ± 0.830 | 0.05 ± 0.716 |
| Change at Cycle 6 Day 35 | 0.43 ± 0.851 | -0.15 ± 1.041 | -0.01 ± 0.771 |
| Change at Cycle 7 Day 28 | 0.48 ± 0.862 | -0.16 ± 1.114 | 0.07 ± 0.743 |
| Change at Cycle 8 Day 28 | 0.56 ± 0.880 | 0.02 ± 1.208 | 0.15 ± 0.811 |
| Change at Cycle 9 Day 35 | 0.58 ± 0.919 | 0.04 ± 1.189 | 0.06 ± 0.822 |
| Change at Cycle 10 Day 28 | 0.66 ± 1.059 | 0.12 ± 1.345 | 0.20 ± 0.584 |
| Change at Cycle 11 Day 28 | 0.63 ± 1.227 | 0.04 ± 1.248 | 0.24 ± 0.825 |
| Change at Cycle 12 Day 35 | 0.66 ± 1.049 | 0.01 ± 1.312 | 0.15 ± 0.682 |
| Endpoint | 0.65 ± 0.992 | -0.07 ± 1.272 | 0.11 ± 0.705 |
The change from baseline in fasting plasma glucose levels was analyzed and reported using a mixed-model for repeated measures.
| Millimoles per liter (mmol/L) | Luteinizing Hormone Releasing Hormone Agonist (LHRHa) | Apalutamide | LHRHa + Apalutamide |
|---|---|---|---|
| Change at Cycle 3 Day 35 | -0.07 ± 0.24 | 0.11 ± 0.23 | 0.61 ± 0.21 |
| Change at Cycle 6 Day 35 | 0.19 ± 0.19 | -0.00 ± 0.19 | 0.27 ± 0.17 |
| Change at Cycle 9 Day 35 | 0.10 ± 0.18 | -0.10 ± 0.19 | 0.41 ± 0.16 |
| Change at Cycle 12 Day 35 | 0.29 ± 0.19 | 0.15 ± 0.19 | 0.26 ± 0.16 |
The change from baseline in HbA1C was analyzed and reported using a mixed-model for repeated measures.
| Percentage of HbA1C | Luteinizing Hormone Releasing Hormone Agonist (LHRHa) | Apalutamide | LHRHa + Apalutamide |
|---|---|---|---|
| Change at Cycle 3 Day 35 | 0.14 ± 0.06 | -0.07 ± 0.06 | 0.06 ± 0.06 |
| Change at Cycle 6 Day 35 | 0.09 ± 0.06 | -0.10 ± 0.06 | 0.08 ± 0.06 |
| Change at Cycle 9 Day 35 | 0.16 ± 0.06 | -0.13 ± 0.06 | 0.04 ± 0.06 |
| Change at Cycle 12 Day 35 | 0.18 ± 0.06 | -0.09 ± 0.06 | 0.13 ± 0.06 |
Change from baseline in cholesterol, HDL cholesterol, LDL cholesterol and triglycerides were analyzed and reported using a mixed-model for repeated measures.
| mmol/L | Luteinizing Hormone Releasing Hormone Agonist (LHRHa) | Apalutamide | LHRHa + Apalutamide |
|---|---|---|---|
| Cholesterol: Change at Cycle 3 Day 35 | 0.34 ± 0.16 | 0.98 ± 0.16 | 1.28 ± 0.13 |
| Cholesterol: Change at Cycle 6 Day 35 | 0.18 ± 0.16 | 0.71 ± 0.16 | 1.35 ± 0.13 |
| Cholesterol: Change at Cycle 9 Day 35 | 0.24 ± 0.16 | 0.66 ± 0.17 | 1.21 ± 0.14 |
| Cholesterol: Change at Cycle 12 Day 35 | 0.38 ± 0.16 | 0.71 ± 0.17 | 0.92 ± 0.15 |
| LDL Cholesterol: Change at Cycle 3 Day 35 | 0.08 ± 0.15 | 0.67 ± 0.15 | 0.91 ± 0.13 |
| LDL Cholesterol: Change at Cycle 6 Day 35 | -0.03 ± 0.15 | 0.36 ± 0.15 | 0.87 ± 0.13 |
| LDL Cholesterol: Change at Cycle 9 Day 35 | 0.01 ± 0.14 | 0.28 ± 0.15 | 0.69 ± 0.13 |
| LDL Cholesterol: Change at Cycle 12 Day 35 | 0.07 ± 0.15 | 0.31 ± 0.16 | 0.57 ± 0.13 |
| HDL Cholesterol: Change at Cycle 3 Day 35 | 0.08 ± 0.04 | 0.07 ± 0.05 | 0.13 ± 0.04 |
| HDL Cholesterol: Change at Cycle 6 Day 35 | 0.09 ± 0.04 | 0.16 ± 0.05 | 0.12 ± 0.04 |
| HDL Cholesterol: Change at Cycle 9 Day 35 | 0.10 ± 0.05 | 0.21 ± 0.05 | 0.17 ± 0.04 |
| HDL Cholesterol: Change at Cycle 12 Day 35 | 0.12 ± 0.05 | 0.21 ± 0.06 | 0.12 ± 0.05 |
| Triglycerides: Change at Cycle 3 Day 35 | 0.27 ± 0.14 | 0.31 ± 0.14 | 0.34 ± 0.12 |
| Triglycerides: Change at Cycle 6 Day 35 | 0.21 ± 0.15 | 0.14 ± 0.15 | 0.52 ± 0.13 |
| Triglycerides: Change at Cycle 9 Day 35 | 0.30 ± 0.15 | -0.01 ± 0.16 | 0.53 ± 0.14 |
| Triglycerides: Change at Cycle 12 Day 35 | 0.43 ± 0.15 | 0.08 ± 0.16 | 0.28 ± 0.13 |
Change from baseline in BMD was assessed for femoral neck and lumber spine with DEXA scans.
| Gram per centimeter square (g/cm^2) | Luteinizing Hormone Releasing Hormone Agonist (LHRHa) | Apalutamide | LHRHa + Apalutamide |
|---|---|---|---|
| Femoral Neck | 0.00 ± 0.03 | 0.07 ± 0.03 | -0.02 ± 0.02 |
| Lumbar Spine | 0.00 ± 0.02 | 0.01 ± 0.02 | -0.06 ± 0.02 |
The time to serum testosterone recovery to \> 50 ng/dL and \> 150 ng/dL from Month 13 to Month 24 of protocol therapy was reported.
| Months | Luteinizing Hormone Releasing Hormone Agonist (LHRHa) | LHRHa + Apalutamide |
|---|---|---|
| > 50 ng/dL | 18.89 (18.04 to 23.95) | 18.10 (17.91 to 24.05) |
| > 150 ng/dL | 23.33 (18.14 to 24.87) | 23.98 (18.00 to 24.08) |
Change from baseline in serum DHT levels was reported.
| Nanomoles per liter (nmol/L) | Luteinizing Hormone Releasing Hormone Agonist (LHRHa) | Apalutamide | LHRHa + Apalutamide |
|---|---|---|---|
| Change at Cycle 6 Day 35 | -0.90 ± 0.26 | 0.93 ± 0.27 | -0.90 ± 0.23 |
| Change at Cycle 12 Day 35 | -0.90 ± 0.24 | 0.86 ± 0.25 | -0.90 ± 0.21 |
Change from baseline in estradiol levels was reported.
| Picomoles per liter (pmol/L) | Luteinizing Hormone Releasing Hormone Agonist (LHRHa) | Apalutamide | LHRHa + Apalutamide |
|---|---|---|---|
| Change at Cycle 6 Day 35 | -88.63 ± 12.24 | 87.87 ± 13.37 | -94.11 ± 11.58 |
| Change at Cycle 12 Day 35 | -77.12 ± 13.46 | 81.29 ± 13.88 | -103.01 ± 12.76 |
An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. Treatment-emergent adverse events are those that occurred between the date of 1st dose of study drug and date of last dose of study drug plus 30 days.
| Percentage of participants | Luteinizing Hormone Releasing Hormone Agonist (LHRHa) | Apalutamide | LHRHa + Apalutamide |
|---|---|---|---|
| Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) | 96.6 | 100.0 | 100.0 |
Collected over Up to 6 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Luteinizing Hormone Releasing Hormone Agonist (LHRHa) | 1/29 (3.4%) | 3/29 (10.3%) | 28/29 (96.6%) |
| Apalutamide | 0/29 (0%) | 0/29 (0%) | 29/29 (100%) |
| LHRHa + Apalutamide | 0/31 (0%) | 5/31 (16.1%) | 30/31 (96.8%) |
| Event | Luteinizing Hormone Releasing Hormone Agonist (LHRHa) | Apalutamide | LHRHa + Apalutamide |
|---|---|---|---|
| Ventricular TachycardiaCardiac disorders | 1/29 | 0/29 | 0/31 |
| VertigoEar and labyrinth disorders | 1/29 | 0/29 | 0/31 |
| Device FailureProduct Issues | 1/29 | 0/29 | 0/31 |
| Toxic Epidermal NecrolysisSkin and subcutaneous tissue disorders | 1/29 | 0/29 | 0/31 |
| Acute Myocardial InfarctionCardiac disorders | 0/29 | 0/29 | 1/31 |
| Angina PectorisCardiac disorders | 0/29 | 0/29 | 1/31 |
| Atrial FibrillationCardiac disorders | 0/29 | 0/29 | 1/31 |
| Wound InfectionInfections and infestations | 0/29 | 0/29 | 1/31 |
| Rib FractureInjury, poisoning and procedural complications | 0/29 | 0/29 | 1/31 |
| Transient Ischaemic AttackNervous system disorders | 0/29 | 0/29 | 1/31 |
| Event | Luteinizing Hormone Releasing Hormone Agonist (LHRHa) | Apalutamide | LHRHa + Apalutamide |
|---|---|---|---|
| Hot FlushVascular disorders | 25/29 | 9/29 | 26/31 |
| FatigueGeneral disorders | 22/29 | 19/29 | 24/31 |
| GynaecomastiaReproductive system and breast disorders | 3/29 | 12/29 | 1/31 |
| Nipple PainReproductive system and breast disorders | 0/29 | 12/29 | 0/31 |
| InsomniaPsychiatric disorders | 2/29 | 1/29 | 10/31 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/29 | 8/29 | 7/31 |
| DiarrhoeaGastrointestinal disorders | 0/29 | 7/29 | 4/31 |
| NauseaGastrointestinal disorders | 2/29 | 4/29 | 7/31 |
| DysgeusiaNervous system disorders | 0/29 | 6/29 | 5/31 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 3/29 | 4/29 | 6/31 |
| Age, Continuous(Years) | Luteinizing Hormone Releasing Hormone Agonist (LHRHa) | Apalutamide | LHRHa + Apalutamide | Total |
|---|---|---|---|---|
| Mean | 67.3 ± 6.51 | 66.1 ± 6.18 | 67.5 ± 6.67 | 67.0 ± 6.42 |
| Sex: Female, Male(Participants) | Luteinizing Hormone Releasing Hormone Agonist (LHRHa) | Apalutamide | LHRHa + Apalutamide | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 30 | 29 | 31 | 90 |
| Ethnicity (NIH/OMB)(Participants) | Luteinizing Hormone Releasing Hormone Agonist (LHRHa) | Apalutamide | LHRHa + Apalutamide | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 3 | 0 | 3 |
| Not Hispanic or Latino | 30 | 26 | 30 | 86 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Luteinizing Hormone Releasing Hormone Agonist (LHRHa) | Apalutamide | LHRHa + Apalutamide | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 2 | 1 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 | 2 |
| White | 26 | 26 | 29 | 81 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 1 | 0 | 3 |
| Region of Enrollment(Participants) | Luteinizing Hormone Releasing Hormone Agonist (LHRHa) | Apalutamide | LHRHa + Apalutamide | Total |
|---|---|---|---|---|
| UNITED STATES | 30 | 29 | 31 | 90 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2013 to primary completion in Mar 2019, 71 months.
Results were first posted in Mar 2020, 1 year after primary completion.
Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 71 months is above that.
Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Apalutamide · Gonadotropin-releasing Hormone Analog
Aragon Pharmaceuticals, Inc. →